Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT05376969

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05376969
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05376969. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-25 (actual); primary completion 2022-05-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
Acronym
ENHANCE-MEXT
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
DWP16001
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct05376969
Content hash
4c67e3987c36153a9b30a697c1e1f20cdd424ebf712b520a0df95bb119bc9613